MENU
+Compare
UPB
Stock ticker: NASDAQ
AS OF
Jan 15, 04:31 PM (EDT)
Price
$31.14
Change
-$1.16 (-3.59%)
Capitalization
1.74B

UPB Upstream Bio Inc Forecast, Technical & Fundamental Analysis

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders... Show more

UPB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for UPB with price predictions
Jan 14, 2026

UPB in downward trend: price expected to drop as it breaks its higher Bollinger Band on January 13, 2026

UPB broke above its upper Bollinger Band on January 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 16 similar instances where the stock broke above the upper band. In of the 16 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UPB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 12, 2026. You may want to consider a long position or call options on UPB as a result. In of 17 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for UPB just turned positive on January 12, 2026. Looking at past instances where UPB's MACD turned positive, the stock continued to rise in of 14 cases over the following month. The odds of a continued upward trend are .

UPB moved above its 50-day moving average on January 07, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where UPB advanced for three days, in of 66 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 56 cases where UPB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. UPB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.608) is normal, around the industry mean (27.929). P/E Ratio (0.000) is within average values for comparable stocks, (51.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.899). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (329.547).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UPB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
UPB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GMJPX8.950.08
+0.90%
Goldman Sachs Real Estate Securities P
HWVAX13.100.11
+0.85%
Hotchkis & Wiley Sm Cp Divers Val A
ABSIX21.030.17
+0.81%
AB Discovery Value I
TRCVX29.730.10
+0.34%
Nuveen Large Cap Value Idx Retire
MUXYX28.39-0.15
-0.53%
Victory S&P 500 Index Y

UPB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, UPB has been loosely correlated with IDYA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if UPB jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UPB
1D Price
Change %
UPB100%
-0.92%
IDYA - UPB
43%
Loosely correlated
+5.53%
VYGR - UPB
41%
Loosely correlated
+2.74%
SYRE - UPB
40%
Loosely correlated
+5.17%
DSGN - UPB
40%
Loosely correlated
+2.40%
ORKA - UPB
40%
Loosely correlated
+2.11%
More